


M.R.A. Pillai

**METALLIC RADIONUCLIDES
AND THERAPEUTIC
RADIOPHARMACEUTICALS**



**INSTITUTE OF NUCLEAR CHEMISTRY
AND TECHNOLOGY**

WARSZAWA 2010

SPIS TREŚCI

1. INTRODUCTION	23
1.1. Glimpse to the history	23
1.2. Author's introduction to the therapeutic radiopharmaceuticals field	26
1.3. References	27
2. THERAPEUTIC RADIOPHARMACEUTICALS	33
2.1. Introduction	33
2.2. Radionuclide therapy	33
2.3. Therapeutic radiopharmaceuticals	34
2.4. Uptake mechanisms of therapeutic radiopharmaceuticals	34
2.5. Therapeutic radiopharmaceuticals development	35
2.5.1. Target	35
2.5.2. Carrier molecule	35
2.5.3. Radionuclide	36
2.5.4. Radiolabeling	36
2.5.5. Biological evaluation	36
2.5.6. Toxicity studies	38
2.5.7. Clinical studies	39
2.6. Applications of therapeutic radiopharmaceuticals	40
2.6.1. Treatment of primary cancer	40
2.6.2. Bone pain palliation	43
2.6.3. Loco-regional application for treatment of primary cancer	44
2.6.4. Radiosynovectomy	45
2.6.5. Intravascular radionuclide therapy (IVRNT)	45
2.7. References	45
3. RADIONUCLIDES FOR TARGETED THERAPY	50
3.1. Introduction	50
3.2. Current demand for therapeutic radiopharmaceuticals	50
3.2.1. Radiopharmaceuticals for primary cancer	50
3.2.2. Radiopharmaceuticals for bone metastasis	51
3.2.3. How much radioactivity will be needed for targeted therapy?	52
3.2.4. Can one find a ^{99m} Tc or ¹⁸ F match for therapy?	52
3.3. Selection of a radionuclide for targeted therapy	53
3.3.1. Decay modes for therapeutic radionuclides	54
3.3.2. Half-life	54
3.3.3. Energy of particles	55
3.3.4. Availability of gamma rays	55
3.3.5. Specific activity	56
3.3.6. Availability and production logistics	58
3.4. Beta particle emitting radionuclides for targeted therapy	60
3.5. Widely used β^- particle emitting radionuclides for radionuclide therapy	64
3.5.1. Iodine-131	64

- 3.5.2. Phosphorous-32 65
- 3.5.3. Strontium-89 65
- 3.5.4. Yttrium-90 66
- 3.5.5. Samarium-153 66
- 3.5.6. Lutetium-177 67
- 3.5.7. Rhenium-188 68
- 3.5.8. Rhenium-186 68
- 3.5.9. Holmium-166 69
- 3.5.10. Erbium-169 69
- 3.5.11. Tin-117m 70
- 3.6. Therapeutic radionuclides less explored but can be prepared in NCA form 70**
- 3.6.1. Rhodium-105 70
- 3.6.2. Terbium-161 71
- 3.6.3. Gold-199 71
- 3.6.4. Praseodymium-143 72
- 3.6.5. Promethium-149 72
- 3.6.6. Silver-111 72
- 3.6.7. Arsenic-77 73
- 3.7. Other β^- emitting radionuclides of interest in radionuclide therapy 73**
- 3.7.1. Arsenic-76 73
- 3.7.2. Dysprosium-165 73
- 3.7.3. Gadolinium-159 74
- 3.7.4. Gold-198 74
- 3.7.5. Hafnium-181 75
- 3.7.6. Palladium-109 75
- 3.7.7. Praseodymium-142 75
- 3.7.8. Scandium-46 75
- 3.7.9. Tantalum-182 75
- 3.7.10. Terbium-160 76
- 3.7.11. Thulium-170 76
- 3.7.12. Ytterbium-175 76
- 3.8. Alpha emitting radionuclides for therapy 77**
- 3.8.1. Actinium-225 78
- 3.8.2. Astatine-211 78
- 3.8.3. Bismuth-212 78
- 3.8.4. Bismuth-213 79
- 3.8.5. Radium-223 79
- 3.8.6. Radium-224 79
- 3.8.7. Terbium-149 79
- 3.8.8. Thorium-227 80
- 3.8.9. Thorium-226 80
- 3.9. Auger electron emitting radionuclides 80**
- 3.10. Conclusions 81**
- 3.11. References 82**

4.	STUDIES ON ^{105}Rh AND LABELED MOLECULES	87
4.1.	Introduction	87
4.2.	Inorganic chemistry of rhodium	87
4.3.	Radionuclidic characteristics of ^{105}Rh	87
4.4.	Production of ^{105}Rh	88
4.5.	Development of ^{105}Rh labeled monoclonal antibodies	89
4.6.	Development of bifunctional chelating agents for rhodium	90
4.6.1.	Design and synthesis of bifunctional chelating agents for rhodium	91
4.7.	Rhodium complexes	91
4.7.1.	Synthesis and X-ray crystal structure of a rhodium (III) complex with an amine phenol ligand	91
4.8.	Coupling of biomolecules with preformed ^{105}Rh complexes	93
4.8.1.	Radiolabeling of proteins with ^{105}Rh using 4-p-toulic acid-diethylenetriamine (PTDET)	94
4.8.2.	Radiolabeling of proteins with ^{105}Rh using 4-(p-aminobenzyl)-diethylenetriamine (ABDET)	95
4.8.3.	Radiolabeling of proteins with ^{105}Rh using 1,7-bis(2-hydroxybenzyl)-4-(p-aminobenzyl)-diethylenetriamine (BHABDT)	96
4.8.4.	Cysteine as a BFCA for radiolabeling proteins with ^{105}Rh	98
4.8.5.	^{105}Rh -hematoporphyrin	98
4.9.	Radiochemical purity evaluation of ^{105}Rh complexes by magnesium oxide adsorption	100
4.10.	Production of ^{105}Rh using natural ruthenium target	101
4.10.1.	Irradiation	102
4.10.2.	Radiochemical processing	102
4.11.	Current status of ^{105}Rh as a therapeutic radionuclide	103
4.12.	Lessons learned from ^{105}Rh radiopharmaceuticals development	103
4.13.	Conclusions	105
4.14.	References	105
5.	RHENIUM RADIOPHARMACEUTICALS	108
5.1.	Introduction	108
5.2.	Inorganic chemistry of rhenium	108
5.3.	Radionuclides of rhenium for therapy	108
5.3.1.	Rhenium-186	109
5.3.2.	Rhenium-188	110
5.4.	Review of rhenium radiopharmaceuticals	111
5.4.1.	Bone pain palliation agents	111
5.4.2.	Rhenium labeled antibodies	112
5.4.3.	Rhenium labeled peptides	112
5.4.4.	^{188}Re -lipiodol for hepatic carcinoma	112
5.4.5.	$^{186/188}\text{Re}$ -colloids for radiosynovectomy	113
5.4.6.	^{188}Re for intravascular radionuclide therapy (IVRNT)	113
5.5.	Development of rhenium radiopharmaceuticals	114
5.5.1.	Synthesis of chelating agents for complexation with technetium and rhenium	114
5.5.2.	Synthesis of $^{99\text{m}}\text{Tc}$ and rhenium complexes with amine phenol ligands	114

5.6. Radiochemical studies with ^{186}Re and ^{188}Re	118
5.6.1. Production of $^{186/188}\text{Re}$	118
5.6.2. MEK extraction of $^{186}\text{ReO}_4$	118
5.6.3. $^{186/188}\text{Re}$ -DMSA	119
5.6.4. $^{186/188}\text{Re}$ -DMSA with reduced renal uptake	120
5.6.5. ^{186}Re -HEDP	121
5.6.6. $^{186/188}\text{Re}$ complexes of polyaminophosphonate ligands	122
5.6.7. ^{186}Re -CTMP	124
5.6.8. ^{186}Re -porphyrin	126
5.7. Studies with generator eluted ^{188}Re	127
5.7.1. ^{188}Re labeled hydroxyapatite particles	127
5.7.2. ^{188}Re -ethylene dicysteine for IVRNT	129
5.7.3. ^{188}Re patches for therapy of skin cancer	130
5.8. Electrochemical $^{188}\text{W}/^{188}\text{Re}$ generator	131
5.9. Post-elution concentration of ^{188}Re obtained from an alumina column	132
5.10. Mixed radionuclide therapy using ^{186}Re and ^{188}Re	133
5.11. Why rhenium radiopharmaceuticals are not widely used in the clinics?	134
5.12. Conclusions	135
5.13. References	136
6. HOLMIUM-166 BASED RADIOPHARMACEUTICALS	142
6.1. Introduction	142
6.2. Inorganic chemistry of lanthanides	142
6.3. Inorganic chemistry of holmium	143
6.4. Production of ^{166}Ho	143
6.4.1. Direct (n, γ) activation of natural holmium targets	143
6.4.2. Production using generator route	144
6.4.3. Production of ^{166}Ho	144
6.5. Development of ^{166}Ho based radiopharmaceuticals	145
6.5.1. ^{166}Ho -HA particles for radiation synovectomy	145
6.6. ^{166}Ho -tracers for IVRNT	147
6.6.1. Preparation of ^{166}Ho -EC complex	147
6.7. Conclusions	149
6.8. References	149
7. YTTERBIUM-175 PRODUCTION AND RADIOPHARMACEUTICALS	152
7.1. Introduction	152
7.2. Inorganic chemistry of ytterbium	152
7.3. Production of ^{175}Yb	152
7.3.1. Radionuclidic purity considerations during production of ^{175}Yb	153
7.4. Production of ^{175}Yb	154
7.5. ^{175}Yb labeled polyaminophosphonates	155
7.5.1. Preparation of ^{175}Yb complexes	156
7.6. Conclusions	158
7.7. References	158

- 8. YTTRIUM-90 PRODUCTION AND RADIOPHARMACEUTICALS DEVELOPMENT 160**
- 8.1. Introduction 160**
- 8.2. Inorganic chemistry of yttrium 160**
- 8.3. Production of ^{90}Y 161**
- 8.3.1. Direct (n, γ) activation of ^{89}Y 161
- 8.3.2. The $^{90}\text{Sr}/^{90}\text{Y}$ generator 161
- 8.4. Development of novel $^{90}\text{Sr}/^{90}\text{Y}$ generator systems 164**
- 8.4.1. Supported liquid membrane (SLM) based $^{90}\text{Sr}/^{90}\text{Y}$ generator 164
- 8.4.2. Electrochemical $^{90}\text{Sr}/^{90}\text{Y}$ generator (Kamadhenu) 165
- 8.4.3. Automation of $^{90}\text{Sr}/^{90}\text{Y}$ generator (Kamadhenu) 167
- 8.4.4. Accreditation 170
- 8.5. Radionuclidic purity requirement of ^{90}Y 171**
- 8.5.1. Extraction paper chromatography for estimation of the radionuclidic purity of ^{90}Y 171
- 8.6. Review of ^{90}Y radiopharmaceuticals 172**
- 8.6.1. Yttrium-90 labeled monoclonal antibodies for treatment of primary cancer 173
- 8.6.2. ^{90}Y labeled peptides 174
- 8.6.3. ^{90}Y labeled particles or colloids 175
- 8.6.4. Other ^{90}Y based radiopharmaceuticals 175
- 8.6.5. Intraoperative avidination for radionuclide therapy (IART[®]) 175
- 8.7. Development of ^{90}Y radiopharmaceuticals 176**
- 8.7.1. Preparation of ^{90}Y labeled particles for use in radiosynovectomy 176
- 8.7.2. ^{90}Y patches skin patches for therapy of superficial tumors 177
- 8.7.3. ^{90}Y -DTPA and ^{90}Y -DOTA for potential application in intravascular radionuclide therapy 178
- 8.8. Conclusions 178**
- 8.9. References 179**
- 9. LUTETIUM-177 PRODUCTION AND RADIOPHARMACEUTICALS 184**
- 9.1. Introduction 184**
- 9.2. Inorganic chemistry of ^{177}Lu 185**
- 9.3. Radionuclidic characteristics of ^{177}Lu 186**
- 9.3.1. ^{177}Lu : a metallic analogue of ^{131}I 186
- 9.4. Production logistics of ^{177}Lu 188**
- 9.4.1. Direct route for production of ^{177}Lu 188
- 9.4.2. Indirect route for production of ^{177}Lu 190
- 9.5. Production of ^{177}Lu 192**
- 9.5.1. Irradiation and radiochemical processing 192
- 9.5.2. Production yields 193
- 9.5.3. Radionuclidic purity 193
- 9.6. Review of ^{177}Lu radiopharmaceuticals 194**
- 9.6.1. ^{177}Lu labeled monoclonal antibodies 194
- 9.6.2. ^{177}Lu labeled peptides 198
- 9.6.3. ^{177}Lu bone pain palliation agents 199

- 9.6.4. ^{177}Lu labeled particulates 200
- 9.6.5. ^{177}Lu small molecules 200
- 9.7. Development of ^{177}Lu based radiopharmaceuticals 200**
 - 9.7.1. Development of ^{177}Lu -phosphonates for bone pain palliation 200
 - 9.7.2. Pharmacokinetics and toxicity studies with ^{177}Lu -EDTMP 206
 - 9.7.3. ^{177}Lu -DOTA-lanreotide 215
 - 9.7.4. ^{177}Lu labeled DOTA-estradiol 219
- 9.8. Conclusions 222**
- 9.9. References 223**
- 10. THULIUM-170 RADIOPHARMACEUTICALS FOR BONE PAIN PALLIATION 231**
 - 10.1. Introduction 231**
 - 10.2. Inorganic chemistry of thulium 231**
 - 10.3. Radionuclidic characteristics of ^{170}Tm 231**
 - 10.4. Radiopharmaceuticals for bone pain palliation 232**
 - 10.5. Why another radionuclide or radiopharmaceutical is needed for bone pain palliation? 234**
 - 10.5.1. ^{153}Sm -EDTMP 234
 - 10.5.2. $^{89}\text{SrCl}_2$ 235
 - 10.6. ^{170}Tm as a cost effective alternative to ^{89}Sr 236**
 - 10.7. Development of ^{170}Tm -EDTMP as a bone pain palliation agent 237**
 - 10.7.1. Production of ^{170}Tm 237
 - 10.7.2. Preparation of ^{170}Tm -EDTMP complex 238
 - 10.7.3. Biological evaluation 238
 - 10.7.4. Scintigraphic imaging 239
 - 10.8. Advantages of ^{170}Tm -EDTMP 240**
 - 10.9. Conclusions 241**
 - 10.10. References 241**
- 11. EPILOGUE 245**
 - 11.1. ^{177}Lu -EDTMP for metastatic bone pain 245**
 - 11.2. Kamadhenu: electrochemical generator for ^{90}Y suitable for radionuclide therapy 246**
 - 11.3. Extraction paper chromatography 246**
 - 11.4. ^{170}Tm -EDTMP for bone pain palliation 247**
 - 11.5. General conclusions 247**